作者:A. A. Shetnev、E. A. Vasilieva、I. K. Proskurina、A. S. Forostyanko、S. I. Presnukhina、M. V. Tarasenko、A. S. Lebedev、S. A. Ivanovskii、A. D. Kotov
DOI:10.1134/s1070428022030071
日期:2022.3
preparative procedure has been developed for the synthesis of a series of new medicinally relevant 3-aryl-5-(aryloxymethyl)-1,2,4-oxadiazoles in 46–66% yields by alkylation of substituted phenols with 3-aryl-5-(chloromethyl)-1,2,4-oxadiazoles in the system K2CO3/KI/DMF. Poorly studied 3-R-4H-1,2,4-oxadiazin-5(6H)-ones were synthesized by a new method based on the reaction of methyl chloroacetate with amidoximes
摘要 已开发出一种制备方法,通过用 3-aryl-5 对取代酚进行烷基化,以 46-66% 的收率合成一系列新的药用相关 3-aryl-5-(aryloxymethyl)-1,2,4-oxadiazoles -(氯甲基)-1,2,4-恶二唑体系K 2 CO 3 /KI/DMF。研究较少的3-R-4 H -1,2,4-oxadiazin-5(6 H )-ones 采用氯乙酸甲酯与偕胺肟在超碱性体系t -BuONa/DMSO反应的新方法合成。合成的浓度高达 250 μg/mL 的化合物对金黄色葡萄球菌、枯草芽孢杆菌、大肠杆菌等敏感菌株无抗菌活性。和荧光假单胞菌,这可能表明它们对人体肠道和粘液菌群的毒性较低。